Andre Goy, MD, John Theurer Cancer Center

Articles

Dr. Goy Discusses Recent Updates in the Treatment of CLL

April 12th 2017

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent updates in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Goy on BR Plus Bortezomib for MCL Treatment

March 15th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of bendamustine and rituximab (Rituxan; BR) plus bortezomib (Velcade) as a potential treatment for patients with mantle cell lymphoma (MCL).

Dr. Goy on Maintenance Strategies in MCL Treatment

February 28th 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses maintenance strategies for treating patients with mantle cell lymphoma.

Dr. Andre Goy Explains Marginal Zone Lymphoma

March 31st 2016

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.

Live From ASH 2015: Galvanizing Blood Cancer Research!

December 14th 2015

It is obviously impossible to summarize all of the significant data from the 2015 ASH Annual Meeting in this column, but I would like to highlight several key emerging trends that continue to illustrate the palpable ongoing revolution happening in cancer care and beyond.

Dr. Goy on John Theurer Cancer Center Milestone

December 9th 2015

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, director, Clinical and Translational Cancer Research, discusses an upcoming event at John Theurer Cancer Center in honor of the institution's 25th anniversary of its first bone marrow transplant.

Clinical Trials: The Elephant in the Room

November 15th 2015

Failed clinical trials come at a huge cost to pharmaceutical sponsors, patients' lives, and society through impact on innovation.

Precision Medicine Carries Significant Challenges but Will (Eventually) Lower Cancer Care Costs and Is the Way to Go (Precisely)

October 19th 2015

Our goal should be to use precision medicine as a way to deliver value-based care.

DNA Damage Response: A Constant Effort to Maintain Cell Integrity Might Help Cancer Patients After All

September 22nd 2015

The continued progress in understanding and deciphering the critical role of the DNA damage response might help us stratify cancer patients in the future and personalize their therapies.

The Cost of Drugs in Cancer Care: A Story of Misalignment, With Necessary (Positive) Changes!

August 19th 2015

The unprecedented, soaring price of anticancer drugs (and cancer care) is not sustainable and has truly not been addressed.

The Evolving Story of Mutational Landscape in Cancer and Its Implications: Bad Luck or Great Hope?

August 17th 2015

The ability to identify which mutations are likely to be "drivers" in cancer pathogenesis and to elucidate how mutated genes affect the biology of a given tumor are fundamental current challenges that might provide hope in cancer genomics in the future.

ASCO 2015: Immuno-Oncology Again Takes Center Stage

June 16th 2015

The ASCO annual meeting has retained its core purpose of providing a unique platform for oncologists to interact and exchange the latest practice-changing research.

A Promising Move Toward Compassionate Access to Drugs

May 22nd 2015

Dr. Andre Goy discusses efforts to improve "compassionate use" programs that expand access to promising drugs that are not yet approved by the FDA.

"The Emperor of All Maladies"-The Amazing Biography of Cancer...Can We Do Even Better?

April 15th 2015

Thanks to the focus on progress in medicine, tremendous progress has been made in oncology, as illustrated in the recent 6-hour Ken Burns and Barak Goodman television documentary on cancer.

Redefining the Role of Pathology in the Molecular Era: Away From the Microscope? Not So Fast

March 21st 2015

Andre Goy, MD, discusses how pathologists will continue to play a critical role in oncology care, even with the technological advances of the molecular era.

The Time Is Right for True Precision Medicine in Oncology

February 13th 2015

We hear the terms individualized, personalized, and precision medicine often used interchangeably. Everyone would agree, however, that the "one-size-fits-all blockbuster drugs/approach" is over.

ASH Meeting Highlights a Great Year and Builds Momentum Toward a New Era in Cancer Care

January 16th 2015

A few weeks ago, physicians and scientists from around the globe gathered in San Francisco for the 2014 American Society of Hematology (ASH) Annual Meeting. Let's review some trends, since there were key develÂopments across the board.

Dr. Goy Discusses the Impact of the Roche/Foundation Medicine Partnership

January 14th 2015

Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche's recent acquisition of the molecular testing company Foundation Medicine.

Clonal Hematopoiesis in Normal Individuals Might Represent a New Way to Approach Blood Cancer Risk and Diagnosis

December 19th 2014

Cancers arise from multiple acquired mutations that presumably occur over many years, as shown in a number of models, particularly in colon cancer.

Dr. Goy Discusses Intensive Therapy for MCL

November 12th 2014

Andre Goy, MD, MS, discusses intensive therapy for the treatment of patients with mantle cell lymphoma (MCL).